Suppr超能文献

法国复杂腹主动脉瘤开窗或分支型血管腔内修复术的两年真实世界研究结果

Two-Year Results on Real-World Fenestrated or Branched Endovascular Repair for Complex Aortic Abdominal Aneurysm in France.

作者信息

Haulon Stéphan, Steinmetz Eric, Feugier Patrick, Magnan Pierre-Edouard, Maurel Blandine, Fabre Dominique, Geng Bo, Doyle Meridith, Twesigye Innocent, Sobocinski Jonathan

机构信息

Aortic Center, Hôpital Marie Lannelongue, Groupe Hospitalier Paris Saint Joseph, Université Paris Saclay, Paris, France.

CHU F. Mitterrand, Dijon, France.

出版信息

J Endovasc Ther. 2025 Oct;32(5):1478-1488. doi: 10.1177/15266028231208653. Epub 2023 Oct 30.

Abstract

PURPOSE

To describe and compare mid-term outcomes from 2 real-world data collection efforts on fenestrated and branched endovascular aortic repair (fbEVAR) for complex abdominal aortic aneurysms (AAAs) in France and to evaluate the potential of health care databases for long-term post-market surveillance (PMS) and continued reimbursement approval.

METHODS

Two real-world studies were conducted in France: a retrospective health care database study (SNDS) and a prospective clinical study. In the SNDS study, data from implantation and/or hospital stays occurring during follow-up were extracted for all patients treated with the study devices from April 2012 to December 2018. In the clinical study, high-risk patients undergoing fbEVAR with the study devices were enrolled consecutively at 15 sites in France from December 2016 to November 2018.

RESULTS

Data from 1073 patients were extracted from SNDS and compared with analogous variables from 186 patients in the clinical study. Most demographic details were similar between studies (SNDS vs clinical: mean age, 71.9 vs 71.8 years; men, 91.0% vs 89.8%), as was 30-day mortality (SNDS: 5.5%, clinical: 4.3%). Patients received custom-made fenestrated or branched devices (SNDS: 80.7%, clinical: 96.2%) or CE-marked Zenith Fenestrated devices (SNDS: 19.3%, clinical: 3.8%). Initial or technical success was above 94% for both studies. Two-year freedom from all-cause mortality was 80.0% (SNDS) and 85.1% (clinical study). Two-year freedom from aneurysm-related mortality was 93.8% (SNDS) and 94.6% (clinical study). Detailed imaging outcomes were not captured within SNDS; however, information on secondary procedures to restore patency was available and used as a surrogate measure for secondary interventions. Two-year freedom from secondary interventions was 73% for the SNDS study. In the clinical study, at 2 years, aneurysm stability or shrinkage was observed in 92.3% of patients, freedom from target vessel primary patency loss was above 95% for all visceral target vessels, and freedom from secondary interventions was 79.1%.

CONCLUSION

Real-world outcomes from the SNDS and clinical study suggest positive mid-term outcomes in high-risk populations following fbEVAR for complex AAAs. The similarities between these studies suggest that the use of health care databases may be an alternative to prospective clinical studies for long-term follow-up and PMS.Clinical ImpactPositive results following endovascular repair of complex abdominal aortic aneurysms are observed from data extracted from both the French health care database and a post-market clinical study despite initial high-risk patient status and diverse center experience. These outcomes parallel more rigorously designed studies and suggest that with careful study design, real-world data collections have high translatable value to add to the clinical understanding of fenestrated and branched endovascular aortic repair (fbEVAR).

摘要

目的

描述并比较法国两项关于复杂腹主动脉瘤(AAA)的开窗和分支型血管内主动脉修复术(fbEVAR)的真实世界数据收集工作的中期结果,并评估医疗保健数据库用于长期上市后监测(PMS)和持续报销批准的潜力。

方法

在法国进行了两项真实世界研究:一项回顾性医疗保健数据库研究(SNDS)和一项前瞻性临床研究。在SNDS研究中,提取了2012年4月至2018年12月期间所有接受研究器械治疗的患者在随访期间的植入和/或住院数据。在临床研究中,2016年12月至2018年11月期间,在法国的15个地点连续招募了接受fbEVAR治疗的高危患者。

结果

从SNDS中提取了1073例患者的数据,并与临床研究中186例患者的类似变量进行了比较。两项研究中的大多数人口统计学细节相似(SNDS与临床研究:平均年龄,71.9岁对71.8岁;男性,91.0%对89.8%),30天死亡率也相似(SNDS:5.5%,临床研究:4.3%)。患者接受定制的开窗或分支器械(SNDS:80.7%,临床研究:96.2%)或获得CE标志的Zenith开窗器械(SNDS:19.3%,临床研究:3.8%)。两项研究的初始或技术成功率均高于94%。两年全因死亡率的无事件生存率在SNDS中为80.0%,在临床研究中为85.1%。两年动脉瘤相关死亡率的无事件生存率在SNDS中为93.8%,在临床研究中为94.6%。SNDS中未获取详细的影像学结果;然而,有关于恢复通畅的二次手术的信息,并将其用作二次干预的替代指标。SNDS研究中两年二次干预的无事件生存率为73%。在临床研究中,两年时,92.3%的患者观察到动脉瘤稳定或缩小,所有内脏靶血管的靶血管初始通畅性丧失的无事件生存率高于95%,二次干预的无事件生存率为79.1%。

结论

SNDS和临床研究的真实世界结果表明,对于复杂AAA患者,fbEVAR术后高危人群的中期结果良好。这些研究之间的相似性表明,使用医疗保健数据库可能是长期随访和PMS的前瞻性临床研究的替代方法。临床影响尽管最初患者风险高且各中心经验不同,但从法国医疗保健数据库和上市后临床研究中提取的数据均显示,复杂腹主动脉瘤血管内修复术后结果良好。这些结果与设计更严谨的研究结果相似,表明通过精心设计研究,真实世界数据收集对于增强对开窗和分支型血管内主动脉修复术(fbEVAR)的临床理解具有很高的可转化价值。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验